Charles River Laboratories has made two changes to its board of directors. Robert Bertolini and Richard Wallman will join the board to replace Nancy Chang, who is resigning to pursue other interest, and Douglas Rogers, who does not intend to stand for re-election.
Bertolini worked at PricewaterhouseCoopers for 20 years before joining Schering-Plough, where he remained until the merger with Merck & Co. Wallman has previously worked at IBM and Honeywell. Both have substantial financial experience.
John Langstaff is to step down as president and CEO of Cangene, a Canadian biotech with contract manufacturing capabilities. Langstaff has led Cangene for 20 years but will now be replaced, on an interim basis, by Mike Graham, the current chief financial officer.
AMRI has named Takeshi Yura as assistant director, medicinal chemistry. Yura has 22 years of discovery chemistry leadership experience from working at Japanese units of Dishman, Pfizer and Bayer.
Lori Henderson has also joined AMRI. Henderson has previously worked at Rand Worldwide and Moldflow and has taken the position of vice president (VP), general counsel and secretary at AMRI.
Pacific Biomarkers (PBI) has promoted Sheri’ DuMond to director of business development. DuMond worked at Novartis and Wyeth before joining the business development team at PBI.
Sonal Deshmukh has joined ACM Global Central Lab as head of project management, Asia Pacific. Deshmukh has worked in central labs for seven years, including time at Super Religare Laboratories.
Synexus has appointed Efim Borodowski as director, international business development. Borodowski joins from Fisher Clinical Services to work with key clients in Germany and Austria.